PTH13: THE APPLICATION OF PORTFOLIO MANAGEMENT TECHNIQUES TO PHARMACEUTICAL R&D PROJECT SELECTION AND COST-EFFECTIVENESS ANALYSIS  by Tran, G & Pang, F
408 Abstracts
characteristics, diagnoses, hospitalizations, professional
fees, medical interventions, medication use, laboratory
tests, and complications. These data were collected from
the first day the patients were admitted in the ICU, until the
day they were transferred to another ward. A trauma phy-
sician, a pharmacist, and an inhalation therapist helped to
develop the Clinical Research Form (CRF). Two research
nurses completed the CRFs, and a clinical research assis-
tant collected cost data.
RESULTS: The use of micro costing is a very reliable way
of estimating treatment costs. However, it was found to
be a long and expensive process. In our study, research
nurses spent up to 8 hours per record to collect the infor-
mation needed to complete the CRF.
CONCLUSION: Given the extensive time needed to realize
micro costing studies, it is understandable that modeliza-
tion has occupied a big place in pharmacoeconomic evalua-
tions. However, in some cases, even modelization cannot
replace micro costing. Alternative ways, such as the use of
administrative databases, should be considered. However,
in Quebec, there is still a need to assess the reliability of us-
ing administrative databases for economic evaluations.
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OBJECTIVES: The objective of portfolio management is
to create the most value from a portfolio of projects. It
attempts to ensure that the projects in the portfolio meet
the strategic goals of the business by determining which
projects are to be funded and at what levels. This study
investigates the application of two portfolio management
techniques involving Monte-Carlo simulation and the
Pearson Index to two diverse situations: pharmaceutical
R&D investment prioritisation decisions and health eco-
nomic evaluations using cost-effectiveness analysis.
METHODS: To assist the decision-maker to prioritise
pharmaceutical R&D projects in which to invest, we con-
structed a model involving Monte-Carlo simulation and
the Pearson Index. This model was applied to data on cost
of development and probability of success for each clinical
development phase (I–III), as well as overall return-on-
investment (ROI) for each project in the drug portfolio. To
assist healthcare policy-makers to select the cost-effective
treatment strategy, we constructed a model using Monte-
Carlo simulation, to incorporate variability in medical re-
source use and unit costs, and the bootstrap method to es-
timate the 95% confidence interval for the incremental
cost-effectiveness ratio (ICER). This model was applied to
data from a multinational health economic trial.
RESULTS: For pharmaceutical R&D investment prioriti-
sation decisions, we derived a probability distribution for
the Pearson Index for each project which was then used to
prioritise project selection in light of uncertainty in devel-
opment costs, success probabilities and overall ROI. In ad-
dition, we derived an estimate of the ICER and its 95%
confidence interval, which was then used to select the cost-
effective treatment strategy.
CONCLUSIONS: Portfolio management techniques can
successfully be used to support the decision-maker in mak-
ing optimal decisions in pharmaceutical R&D project se-
lection and to select the cost-effective treatment strategy in
light of the uncertainty/variability in input parameters.
